Nebilet (Nebivolol)

Nebivolol works by selectively antagonising β1‑adrenergic receptors in the heart, which slows heart rate and reduces contractility. In addition, it enhances endothelial nitric oxide release, causing vasodilation and lowering peripheral vascular resistance. This dual action contributes to its antihypertensive and heart‑failure benefits.

The dose of nebivolol is individualized by the prescribing clinician based on the patient’s clinical condition, blood pressure response, and tolerability. Physicians start with a low dose and may titrate upward as needed; exact dosing regimens should always follow the prescriber’s instructions.

Safety data for nebivolol during pregnancy and lactation are limited. It should only be used when the potential maternal benefit justifies any possible risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss risks and alternatives with their healthcare provider.

To request Nebilet, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will ask for trade or institutional credentials. The team then replies with pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Nebivolol is a highly selective β1‑blocker with additional nitric‑oxide‑mediated vasodilatory properties, which may result in better tolerability, especially regarding metabolic effects and sexual dysfunction. Compared with non‑selective beta blockers, nebivolol often produces fewer bronchospastic events and may have a more favourable impact on endothelial function.

Nebilet tablets should be stored at room temperature, below 25 °C, in the original container to protect them from moisture and light. Keep the product out of reach of children and avoid storing in humid or excessively hot environments.

Nebilet is taken orally as a whole tablet, swallowed with a glass of water. It may be taken with or without food, but the same conditions should be maintained daily to ensure consistent absorption. Patients should follow the dosing schedule prescribed by their clinician.

Serious adverse events include severe bradycardia, high‑grade atrioventricular block, marked hypotension, acute worsening of heart failure, bronchospasm in susceptible individuals, and rare allergic reactions such as angioedema. Prompt medical attention is required if any of these symptoms occur.

Nebilet is contraindicated in patients with severe bradycardia (heart rate <50 bpm), second‑ or third‑degree AV block, cardiogenic shock, uncontrolled asthma or severe chronic obstructive pulmonary disease, and in those with known hypersensitivity to nebivolol or any excipients. Clinicians should assess each patient’s medical history before prescribing.